- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: GSK1349572,S/GSK1349572 中文名稱:度魯特韋,德羅格韋
Dolutegravir是一種兩個金屬結(jié)合的HIV integrase抑制劑,無細胞試驗中IC50為2.7 nM,對耐Raltegravir的顯著突變體Y143R,Q148K,N155H,和G140S/Q148H具有適度的活性。
Dolutegravir Chemical Structure
CAS: 1051375-16-6
Cahn P, et al. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318.
Spagnuolo V, et al. Drug Des Devel Ther. 2019 Jan 24;13:477-479.
相關(guān)靶點 | HIV-1 Integrase HIV-2 Integrase HIV Integrase | 點擊展開 |
---|---|---|
相關(guān)產(chǎn)品 | MK-2048 BMS-707035 | 點擊展開 |
相關(guān)化合物庫 | 抗感染化合物庫 抗生素化合物庫 抗病毒化合物庫 抗寄生蟲藥物庫 腸道微生物代謝物庫 | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
HOS | Antiviral assay | 3 hrs | Antiviral activity against HIV-1 harboring wild type integrase infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.0016 μM. | 24901667 | |
HEK293T | Antiviral assay | 2 days | Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days, IC50 = 0.0017 μM. | 23845180 | |
MT4 | Antiviral assay | 4 to 5 days | Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells after 4 to 5 days by bioluminescence assay, IC50 = 0.002 μM. | 23845180 | |
HOS | Antiviral assay | 3 hrs | Antiviral activity against raltegravir-resistant HIV-1 harboring integrase N155H mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.0036 μM. | 24901667 | |
HOS | Antiviral assay | 3 hrs | Antiviral activity against raltegravir-resistant HIV-1 harboring integrase Y143R mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.0043 μM. | 24901667 | |
HOS | Antiviral assay | 3 hrs | Antiviral activity against raltegravir-resistant HIV-1 harboring integrase G140S/Q148H double mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.0058 μM. | 24901667 | |
HOS | Antiviral assay | 3 hrs | Antiviral activity against INSTI-resistant HIV-1 harboring integrase R263K mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.011 μM. | 24901667 | |
HOS | Antiviral assay | 3 hrs | Antiviral activity against INSTI-resistant HIV-1 harboring integrase G118R mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.013 μM. | 24901667 | |
P4R5 MAGI | Antiviral assay | 24 hrs | Antiviral activity against HIV1 infected in CD4/CXCR4/CCR5 expressing human P4R5 MAGI cells preincubated with cells for 24 hrs followed by viral infection measured after 48 hrs by beta-galactosidase reporter gene assay, EC50 = 0.02 μM. | 30031976 | |
P4R5 | Antiviral assay | 24 hrs | Antiviral activity against HIV1 infected in CD4/CXCR4/CCR5 expressing human P4R5 cells assessed as inhibition of viral replication preincubated with cells for 24 hrs followed by viral infection measured after 48 hrs by beta-galactosidase reporter gene ass, EC50 = 0.02 μM. | 28525279 | |
HEK293T | Antiviral assay | 2 days | Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days in presence of human serum albumin, IC50 = 0.022 μM. | 23845180 | |
Vero E6 | Antiviral assay | 2 days | Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days, EC50 = 22.04 μM. | ChEMBL | |
Vero E6 | Antiviral assay | 2 days | Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days, EC90 = 42.81 μM. | ChEMBL | |
MDCK2 cells | Function assay | Inhibition of human OCT2 expressed in MDCK2 cells using [14C]metformin as substrate by liquid scintillation counting analysis | 23132334 | ||
MDCK2 | Function assay | Inhibition of human OCT2 expressed in MDCK2 cells using [14C]metformin as substrate by liquid scintillation counting analysis, IC50 = 1.9 μM. | 23132334 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Dolutegravir是一種兩個金屬結(jié)合的HIV integrase抑制劑,無細胞試驗中IC50為2.7 nM,對耐Raltegravir的顯著突變體Y143R,Q148K,N155H,和G140S/Q148H具有適度的活性。 | ||
---|---|---|---|
特性 | 新一代兩種金屬結(jié)合的HIV整合酶鏈轉(zhuǎn)移抑制劑。 | ||
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | S/GSK1349572對來自整合酶抑制劑-天然HIV-2感染患者的9種臨床分離株表現(xiàn)出有效的抑制作用,EC50范圍為0.2 nM -1.4 nM。[1] 在體外,S/GSK1349572抑制重組HIV-1整合酶催化的鏈轉(zhuǎn)移,IC50為2.7 nM。此外,S/GSK1349572有效抑制細胞中HIV復制,如作用于感染自身滅活的PHIV慢病毒載體的外周血單核細胞(PBMCs),MT-4 細胞和CIP4細胞,EC50分別為0.51 nM,0.71 nM和2.2 nM。[2] 在體外,S/GSK1349572對5種不同的非核苷逆轉(zhuǎn)錄抑制劑抗性病毒,或核苷逆轉(zhuǎn)錄抑制劑抗性病毒表現(xiàn)出有效的活性,EC50范圍為1.3 nM -2.1 nM。與抗野生型病毒類似,S/GSK1349572對兩種蛋白酶抑制劑抗性病毒表現(xiàn)出同樣的活性,EC50為0.36 nM和0.37 nM。[2] |
|||
---|---|---|---|---|
激酶實驗 | 體外鏈轉(zhuǎn)移試驗 | |||
S/GSK1349572和其他INIs的抑制效能通過鏈轉(zhuǎn)移試驗使用重組HIV整合酶測量。整合酶和生物素化預處理的供體DNA-鏈霉親和素包被的閃爍迫近測定(SPA)珠復合物,通過將2 μM純化的重組整合酶與0.66 μM生物素化供體DNA-4 mg/mL鏈霉親和素包被的SPA珠在25 mM 嗎啡啉丙磺酸鈉(MOPS) (pH 7.2),23 mM NaCl,和10 mM MgCl2于37 °C下培養(yǎng)5分鐘制備。將這些珠子離心,并與稀釋的INIs在37 °C下預培養(yǎng)60分鐘。然后加入3H-標記的靶DNA底物,得到底物終濃度為7 nM,將鏈轉(zhuǎn)移反應(yīng)混合物在37 °C下培育25到45分鐘,使供體DNA到放射性標記的靶DNA鏈轉(zhuǎn)移線性增加。信號使用Wallac MicroBeta閃爍酶標儀讀取。 | ||||
細胞實驗 | 細胞系 | MT-4 | ||
濃度 | 0到10 μM | |||
孵育時間 | 4天或5天 | |||
方法 | 以500000 或 600000 /mL的密度指數(shù)生長的MT-4細胞用HIV-1菌株IIIB感染,病毒感染率為0.001,或50%組織培養(yǎng)感染劑量為4-10。隨后將細胞等份接種到含有不同濃度S/GSK1349572的96孔板。培養(yǎng)4到5天后,抗病毒活性通過細胞活性試驗測定,即用CellTiter-Glo熒光試劑測量生物發(fā)光,或使用黃色四唑MTT試劑[3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴鹽]測量560和 690 nm下的吸光度確定。 |
|||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Dose-response infectivity curves | NL4.3IN(WT) / NL4.3IN(S230R) virus | 29617824 |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT06281834 | Not yet recruiting | Pediatric HIV Infection|Latent Tuberculosis |
Brigham and Women''s Hospital|APIN Public Health Initiatives|University of Cape Town |
May 2024 | Phase 1 |
NCT05122026 | Recruiting | HIV Seropositivity|Pregnancy|Tuberculosis Infection |
The Aurum Institute NPC|Johns Hopkins University|Weill Medical College of Cornell University|University of Washington |
January 17 2024 | Phase 1|Phase 2 |
NCT05069688 | Recruiting | Pediatric HIV Infection|Tuberculosis Infection |
Brigham and Women''s Hospital|APIN Public Health Initiatives|University of Cape Town |
July 7 2023 | Phase 1 |
NCT05122767 | Recruiting | Tuberculosis|HIV |
The Aurum Institute NPC|Johns Hopkins University |
May 24 2023 | Phase 1|Phase 2 |
分子量 | 419.38 | 分子式 | C20H19F2N3O5 |
CAS號 | 1051375-16-6 | SDF | Download Dolutegravir SDF |
Smiles | CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 84 mg/mL ( (200.29 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項